Why Is Celldex Therapeutics (CLDX) Stock Down -17.26% Today?
Key Takeaways
- Celldex Therapeutics shares fell roughly 17.26%, trading near $31.35, down from a prior close of $37.89.
- The decline reflects a classic "sell-the-news" reaction to positive Phase 3 results for its lead drug candidate, barzolvolimab.
- Both the EMBARQ-CSU1 and EMBARQ-CSU2 trials met their primary and key secondary endpoints in chronic spontaneous urticaria (CSU).
- The stock had rallied into the readout near its 52-week high, meaning strong data was already largely priced in.
- A Biologics License Application (BLA) is not expected until 2027, leaving commercialization years away.
- Investors are watching whether shares stabilize near 52-week lows and how upcoming medical-conference data is received.
Opening Summary
Celldex Therapeutics, Inc. (CLDX), a clinical-stage biotechnology company developing antibody-based therapies for inflammatory, allergic, and autoimmune diseases driven by mast cell biology, saw its shares plunge on Tuesday. The stock fell approximately 17.26% to around $31.35, down from a prior-session close of $37.89. The move came despite the company reporting positive topline results from two Phase 3 trials of barzolvolimab, its investigational treatment for chronic spontaneous urticaria, or hives. Markets interpreted the outcome as a case of robust data failing to exceed lofty, pre-positioned expectations, triggering a sharp unwinding of bullish bets.
A "Sell-the-News" Reaction to Positive Phase 3 Data
The immediate catalyst behind the decline was the release of topline results from the EMBARQ-CSU1 and EMBARQ-CSU2 studies, which together enrolled 1,939 patients across more than 500 sites in 43 countries. Both trials met their primary endpoint of mean change in the urticaria activity score at week 12, as well as all key secondary endpoints across both dose groups, with efficacy maintained or even strengthening through week 24. Complete remission rates in treated patients reached as high as 54% at week 24, roughly four times the placebo rate.
Rather than rewarding these results, the market sold the stock in a textbook binary-event reversal. Shares initially spiked to around $41.62 in premarket trading before reversing sharply, at one point falling toward $23.86 and approaching the stock's 52-week low of $22.10. The magnitude of the efficacy results, while clinically positive, did not clear the elevated bar that investors had embedded in the share price ahead of the announcement.
Lofty Expectations and a Crowded Trade
In the weeks leading up to the readout, CLDX had climbed toward its 52-week high of $45.14, with several analysts maintaining price targets above $50. This positioning signaled that a strong result was already widely anticipated. When the data landed in line with — but not dramatically better than — those expectations, momentum-oriented and event-driven investors moved to lock in gains.
Investor caution was compounded by a broader pattern of pipeline uncertainty. In July 2026, barzolvolimab's Phase 2 trial in prurigo nodularis failed to meet its primary endpoint, tempering enthusiasm about the drug's expansion potential beyond CSU. With a BLA submission now guided for 2027 and meaningful revenue still years away, some holders appeared unwilling to maintain positions at elevated valuations through an extended pre-commercial waiting period.
Market Context and Trading Activity
The decline was overwhelmingly company-specific. Broader indices offered no cushion on the day: the S&P 500 was little changed, the Dow Jones Industrial Average edged higher, and the Nasdaq traded slightly lower. Peers in the inflammatory-disease biopharmaceutical space did not experience comparable, catalyst-driven moves, underscoring that CLDX's sell-off stemmed from its own event dynamics rather than sector-wide or macroeconomic headwinds. Trading volume was notably elevated as event-driven investors repositioned, consistent with the unwinding of a heavily anticipated binary catalyst.
What Comes Next for CLDX
Looking ahead, attention turns to how CLDX digests the post-announcement decline and whether the stock can find footing near multi-month lows. The company plans to submit a Biologics License Application in 2027 and will present additional data from the EMBARQ program at upcoming medical conferences, which could provide further clarity on barzolvolimab's durability and differentiation against existing CSU therapies. Key uncertainties include the timing and completeness of the regulatory filing, the commercial competitive landscape in urticaria, and the drug's performance in adjacent indications after the earlier prurigo nodularis setback. As a clinical-stage company without approved products, results will continue to hinge on binary clinical and regulatory milestones.
Trending AI Robots
Tickeron's Trending AI Robots page highlights the strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, with each bot varying by strategy, timeframe, performance metrics, and the symbols it trades. Only the most consistent performers are curated into this section, helping traders identify strategies that are adapting well to today's market environment. Explore the Trending AI Robots to discover tools that may complement your market analysis.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
CLDX in downward trend: price dove below 50-day moving average on September 15, 2026
CLDX moved below its 50-day moving average on September 15, 2026 date and that indicates a change from an upward trend to a downward trend. In 40 of 46 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 87%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 15, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CLDX as a result. In 69 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
The Moving Average Convergence Divergence Histogram (MACD) for CLDX turned negative on August 19, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 37 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.
The 10-day moving average for CLDX crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CLDX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 78%.
The Aroon Indicator for CLDX entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CLDX's RSI Indicator exited the oversold zone, 26 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 46 of 59 cases where CLDX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
Following a +1.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where CLDX advanced for three days, in 208 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
CLDX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. CLDX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.202) is normal, around the industry mean (25.951). P/E Ratio (0.000) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. CLDX's P/S Ratio (10000.000) is very high in comparison to the industry average of (436.793).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CLDX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of immunotherapy technologies for the treatment of cancer and other diseases
Industry Biotechnology
Advertisement